UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

The City and County of San Francisco, et al.,))
Plaintiffs,) 3:18-cv-07591-CRB
v.) San Francisco, California) May 19, 2023
Purdue Pharma, L.P., et al.,) 10:00 a.m.
Defendants.))

BEFORE: THE HONORABLE CHARLES R. BREYER, JUDGE

REPORTER'S TRANSCRIPT OF PROCEEDINGS

STATUS CONFERENCE

Hybrid/Remote Platform

Official Court Reporter:
Teri Veres, RMR, CRR
Sandra Day O'Connor U.S. Courthouse, Suite 312
401 West Washington Street, Spc. 38
Phoenix, Arizona 85003-2151
(602) 322-7251

Proceedings Reported by Stenographic Court Reporter Transcript Prepared by Computer-Aided Transcription

1	APPEARANCES
2	For the Plaintiffs:
3	LIEF, CABRASER, HEIMANN & BERNSTEIN, LLP By: Elizabeth J. Cabraser, Esq.
4	Richard Martin Heimann, Esq. Paulina do Amaral, Esq.
5	275 Battery Street, 29th Floor San Francisco, California 94111-3339
6	SIMMONS HANLY CONROY
7	By: Jayne Conroy, Esq. 112 Madison Avenue, 7th Floor
8	New York, New York 10016
9	SAN FRANCISCO CITY ATTORNEY'S OFFICE By: Sara Jennifer Eisenberg, Esq.
10	1390 Market Street, 6th Floor San Francisco, California 94102
11	ROBBINS GELLER RUDMAN & DOWD, LLP
12	By: Aelish Marie Baig, Esq. Post Montgomery Center
13	One Montgomery Street, Suite 1800 San Francisco, California 94101
14	ban Francisco, carriornia 71101
15	For the Defendant Walgreens:
16	BARTLIT BECK HERMAN PALENCHAR & SCOTT, LLP By: Brian Charles Swanson, Esq.
17	54 W. Hubbard, Suite 300 Chicago, Illinois 60654
18	
19	
20	
21	
22	
23	
24	
25	

1 PROCEEDINGS 2 (The proceedings started at 10:00 a.m.) 3 COURTROOM DEPUTY: All rise, court is now in 4 session. The Honorable Charles R. Breyer presiding. 5 You may be seated. 6 Calling civil action C18-7591, City and County of 7 San Francisco, et al., versus Purdue Pharma, et al. 8 Counsel, please state your appearances for the 9 record and speak into the microphone. Thank you. 10 MS. CABRASER: Good morning, Your Honor, Elizabeth 11 Cabraser; Lieff, Cabraser, Heimann & Bernstein for plaintiff. 12 THE COURT: Morning. 13 MR. HEIMANN: Good morning, Your Honor, Richard 14 Heimann also for plaintiff. 15 THE COURT: Morning. 16 MS. CONROY: Morning, Your Honor, Jane Conroy; 17 Simmons Hanly Conroy for plaintiff. 18 THE COURT: Morning. MS. BAIG: Good morning, Aelish Baig with Robbins 19 20 Geller for the plaintiff. 21 MS. DO AMARAL: Good morning, Your Honor, Paulina do 2.2 Amaral of Leiff, Cabraser for the plaintiff. 23 MS. EISENBEERG: Good morning, Your Honor, Sara Eisenberg, San Francisco City Attorney's Office for the 24 25 plaintiff.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

25

MR. SWANSON: Good morning, Your Honor, Brian Swanson; Bartlit Beck for Walgreens. Nice to see you. THE COURT: Nice to see you, Mr. Swanson. Good morning, thank you for coming in. I understand you have an announcement -- well, there was an announcement, but you may want to present it formally to the Court. So, Ms. Cabraser, if you are the spokesperson. MS. CABRASER: I'm happy to start, Your Honor, and we're happy to answer any questions the Court may have. Yes, as Your Honor is aware, we've reached an agreement with Walgreens to resolve plaintiffs' claims. We've filed a status report with the Court that summarizes the terms of the agreement. This is subject to formal approval, of

course, by the San Francisco Board of Supervisors, which will take place hopefully early this fall, at which point the claims will be dismissed and a consent judgment will be entered with the Court.

The monetary terms of the agreement provide for

The monetary terms of the agreement provide for payment of approximately 230 million dollars over a term of fifteen years with the majority of that, approximately 208 million dollars, to be paid over the first eight years. The payment schedule is consistent with the payment schedule for the Walgreens national settlement with cities and counties and states across the country, which is in progress and which we hope will become effective at the end of this month.

2.2

The Walgreens settlement is in addition to the previously-announced settlement agreements with Teva and Allergan, the other trial defendants, which total approximately 58 million dollars.

So with respect to those three settlements, the recoveries for plaintiff total approximately 288 million dollars, and we have every hope that these will be formally approved by plaintiffs and we'll be able to formally enter consent decrees and dismissals in this case.

We also wanted to thank the Court for presiding over the case and the trial, keeping us on a brisk pace and making this day possible. Thank you.

THE COURT: Thank you. Let me ask some questions.

First of all, congratulations. Obviously, there was a great deal of work that went in to the resolution of the case. I think we all know procedurally where it was. The Court had heard approximately two, two and a half months of testimony. The Court had rendered a very brief judgment order. I think it was only 112 pages of findings and obviously -- maybe it's not obvious. It was obvious to me because I wrote it that a great deal of work went in to the witness' preparation and the presentation of the case. This simply wasn't, "Let's phone it in. Let's submit a few declarations."

To the contrary. It was a case of extensive

2.2

testimony, both in person and by Zoom by both sides. Also, I would say it was testimony and evidence that was thoroughly and skillfully cross-examined by defense counsel, not just Mr. Swanson but his colleagues who are here representing other entities; and so it had the test of being tested, and that was enormously helpful to the Court in forming its findings and its conclusions.

So that's -- that's what I wanted to say about that; and No. 2, obviously -- maybe it wasn't, but it was obvious to me -- the Court was prepared to move ahead for what I would have thought the more difficult aspect of the case, which is, one, quantify the damages and Walgreens responsible for some portion of the damages and, two, make a determination as to what programs -- I'll use that in a large sense -- what programs could successfully address the opioid crisis and its abatement.

After all, I wasn't to hold a damage trial. I was to hold an abatement trial, and the damages were, I think, relatively easy to prove. Abatement, that is, what works to stop this ongoing crisis, is a more complicated question.

However, that is no longer my task. My task has been basically completed. It is now the task of the plaintiffs, the Mayor of the City and County of San Francisco and members of the Board of Supervisors to determine how this money is to be spent.

2.2

So, I would -- a couple of comments on that. First, I would urge the Mayor and members of the Board of Supervisors to take off their political cap and put on their judgmental cap, because they now have to render judgments, and I urge them to do it based upon evidence and not political considerations for how this money is to be spent in order to abate this nuisance.

That's not a simple task, but I'd like to give them one word of guidance -- one word, maybe a whole sentence of guidance. Do not be governed by special interests in making an allocation of funds because we're not talking about special interest. We're talking about special needs, and that's a very different thing.

It's not a function of political input. It's not a function of political groups. It's not a function of special interest groups. It's, rather, a function of, as any doctor would do, any professional fireman, policeman would do, is you look at the crisis and you try to figure out what -- what you can do to try to abate it. Now, it may be that people have arguments one way or the other as to how to allocate these funds.

I understand that, but I also understand that I spent two and a half months listening to a group of people that I consider experts in that regard, doctors at San Francisco General Hospital, emergency service doctors who work

2.2

for the City and County of San Francisco, doctors who work for UCSF in its broadest sense, ambulance workers, police officers, firearm -- fire personnel, chief and so forth, park and recreation officers and workers there and a multitude -- and first responders, librarians, who simply told the Court something that was in plain sight to everybody in San Francisco, which was, there was a crisis.

That crisis was in plain view. That crisis was in the streets. That crisis was in sidewalks. That crisis was in libraries, playgrounds. It was obvious. So I think the expertise as to what should be done rests with the City and County of San Francisco.

I think they have it, and the question is: Do they have the will to implement a remedial abatement project notwithstanding that many people out there will have their causes, their views, their issues as to how the City should be run asking for these funds. That is of concern to me.

Why is it of concern to me? Well, it's of concern to me in this particular case, but it's broader than that.

After all, I'm not -- it may not be apparent to you. I'm older than 40 so I remember the tobacco litigation. None of you remember -- oh, maybe you might, the tobacco litigation.

I apologize for that rather anxious point of my finger, Mr. Heimann; but what happened in that was a vast sum of money was paid by the tobacco industry to try to abate the

2.2

nuisance caused by -- and I say "nuisance." It's a health crisis caused by tobacco, and those funds went into a general fund.

So it paid for any number of things, and I'm not saying that money wasn't -- was addressed to frivolous concerns. I'm just saying it was addressed to other concerns, and, you know, that lesson is everywhere in our political system.

The lottery was supposed to save our school system.

Well, how's that working? Because, in fact, what's happened with the lottery is that the Legislature counts on these funds coming in from the lottery and then reduces its allocation, its designation of funds that it needs to support schools.

So I'm not an un -- I have a realistic sense of it, and I am telling you that it is of great concern to this Court that these funds be used exclusively for the abatement of the opioid crisis.

Now having said that, I've reviewed the Settlement Agreement. I don't see anything in the Settlement Agreement that requires that. I don't know how you can do it, though I think you can by way of ordinance, but I also think -- you're the only one here but I think -- I think, Mr. Swanson, Walgreens has a real interest in how this 230 million dollars is spent.

You have said publicly, and I accept you on your

2.2

representations, clearly, that Walgreens wants to see, "Are these funds used for addressing the opioid crisis?" So you're paying the money, and I would hope that when you pay the money you've got some strings attached to that payment, you know.

You're -- in my view, you're in the negotiating position at this point. I'm not in a negotiating position.

I'm just in a -- as a friendly observer, maybe not too friendly observer. So that is what I'm saying in that regard.

I don't want to see this money go to potholes, though, goodness, we all drive in these streets so the temptation may be strong; but that's not where it belongs, and if you're prepared to say it, Ms. Cabraser -- I'm talking to the City Attorney.

Do you want -- let the City Attorney respond to what I've said, because, basically, they're the principal in the case; and by the way, maybe I've overlooked something, which won't be the first time.

MS. EISENBERG: Thank you, Your Honor. Thank you for the opportunity to respond.

So the settlement with Walgreens does say that the money that Walgreens is paying is to be used for opioid remediation, and "opioid remediation" is a defined term saying that it is for the care, treatment and other programs and expenditures to address the misuse and abuse of opioid products. So there are terms in the settlement --

2.2

THE COURT: I was missing a word in that, the word "exclusively." You see, I don't want to see something where, okay, ten dollars goes here and a million dollars goes there.

I think the word should be "exclusively" and otherwise -- by the way, I'm not drafting it. I have no authority to draft it. I shouldn't draft it, and I'm just saying that there has to be -- or should be in this Settlement Agreement absolute clarity that these funds can be used for this purpose and this purpose only.

Maybe the Board of Ed -- the Board of Education, I go back to my family. Maybe the Board of Supervisors would find that unacceptable. Well, okay, they do. If they do, they do and they don't have to accept it; but I don't want this to be a pot out there where everybody dips into it depending on their political might.

I know I am talking to a political entity, I got that. I understand that, but that doesn't mean the political entities can't comport with judicial suggestions. After all, let's get real here. The success of this litigation depended entirely on your ability -- not you personally, but litigants to come to a court. It was a court that got you -- your redress of your grievances, and that's where the system's designed.

Sometimes it can be done by chatting, by talking, by working things out, and sometimes it doesn't; and so then

2.2

people go to court to resolve disputes, to set parameters, to ensure that rights are appropriately addressed, and that's what happened here and I would -- I want to offer more comments.

No. 1, I want to tell you that I think that there's a disclosure of the fee -- of the fee payment. I think that's entirely appropriate. I think the amount is appropriate. I think the work done on all sides was superb. There was no failure -- and I also think but for the quality of the litigation in this case there wouldn't have been this result.

So no attorney has to apologize for what they've done here. They've done -- they've done very important work and they've done it well, and I want to also say to Walgreens and to Mr. Swanson, I thought your presentation was not only professional, it was civil, it was highly ethical, and it brought to the table the best that one wants to see in litigation in this court; and I want to thank you and your colleagues in difficult circumstances.

I don't -- I'm not naive. You're trying this case in San Francisco in the middle of -- surrounded by the opioid crisis. It's not theoretical and you never made it theoretical, and you also were able in a professional way to work with lawyers on all sides and it was -- it was very valuable for the Court to have your presentation and thank you so much.

2.2

So I don't know where you want to take this. I'd be delighted to talk to the Mayor of San Francisco and the President of the Board of Supervisors if they seek any clarity or want to tell me, "Judge, you just don't have authority here. This is a settlement. We'll use it as we see fit."

They want to say that, they can say that; but I think there is something to be said about full disclosure.

There's a public and the public is affected by it, and we all stand in some relation to the public that they are due an explanation of what happens in litigation. What their input is, I don't know. Sometimes it's useful and sometimes it ought not to be considered in arriving at legal decisions; but here, with this opioid crisis, which is ongoing, I think that it bears some further public discussion.

So that's what I have to say, probably surprised -I don't think it surprises anybody when I come out on the
bench I'm going to say something. Maybe a little
unanticipated; but, you know, that's my job. That's why I'm
here. Another judge could be here and do the same thing.
It's not really a question of personality. It's a question of
perspective. It's a question of roles. It's a question of
what is this institution as an independent branch of
government. So it's enormously important; and I'm sure,
Ms. Eisenberg, you appreciate it.

MS. EISENBERG: I appreciate your comments and,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

25

certainly, the intent of the City Attorney's Office in bringing this case was to get resources to bring to bear on the opioid pandemic which is, as you said, a crisis in San Francisco right now. It was the entire purpose of this case. certainly the intent of the Settlement Agreement that the money be used for opioid remediation purposes as it is --THE COURT: "Exclusively," start using that word. I understand. Yes, exclusively. MS. EISENBERG: That is certainly what -- the entire city is dedicated to trying to make the most of this settlement to help abate this crisis that we are facing. I understand your point about "exclusively." I will make sure that your point is relayed to the decision makers on the funding side and your offer to meet with them is relayed as well. Thank you. THE COURT: Thank you very much. Mr. Swanson, thank you for coming out. MR. SWANSON: Nice to see you, Your Honor. Nice to see my friends across the aisle, too. Ms. Cabraser, anything further? THE COURT: MS. CABRASER: Just to provide some additional context on opioid remediation, which is a defined term in the San Francisco settlement, it's also a defined term in all of the national settlements; and not only is it a defined term in

2.2

those settlements, but each of those settlements, including the national settlement with Walgreens, the other pharmacy defendants, Teva and Allergan, going back to the distributor settlement, includes an exhibit, I think it's called Exhibit G.

Those settlement agreements in Exhibit G is posted on nationalopioidsettlement.com, and that is a lengthy description of all of the programs that have been agreed upon on a national level by Attorneys General, cities and counties, to comprise the universe of opioid remediation; and, indeed, those settlements do provide that other than costs and attorneys' fees, all of that money does get used exclusively for opioids remediation within the four corners of that very detailed and very lengthy exhibit.

Not every locality will use the funds in the same way because the crisis presents differently in different places, but there was great concern both by plaintiffs, cities, counties, Attorneys General, and by the defendants, who are providing these funds, that those funds do get used for those purposes, learning a lesson from the tobacco litigation; and there is ongoing scrutiny over the terms of years of all of these settlement agreements, but that is how the funds are to be used.

Indeed, there are reporting requirements that must be complied with on an annual basis by all of the entities

2.2

that receive those funds. The San Francisco Walgreens agreement is by no means as lengthy and detailed as the national agreement, but it is designed to be fully consistent with it because it's a component of this national program that is intended to transform hard-fought and challenging litigation into funds to be used to address this crisis, both locally and nationally; and I just wanted to make sure that the Court is aware of that and that will be appropriately reflected in what is filed in this court when these agreements are final.

THE COURT: Thank you, Ms. Cabraser.

MS. EISENBERG: Apologies, just want to make one more point about the exhibit that Ms. Cabraser was just talking about --

THE COURT: Yes.

MS. EISENBERG: -- which is a component of some, but not all of the settlement agreements; but is certainly the guiding principle for how the City intends to spend the money, in part, because that exhibit was created in consultation with many of the very experts that you refer to who you heard testify in this trial.

So they were consulted in terms of coming up with the list of what are the appropriate remedies to abate the nuisance, and so their input has already been baked into that exhibit, which is integral to many settlement agreements.

```
1
              THE COURT: Well, thank you. That's also very
2
    helpful. I appreciate it.
 3
              So unless there's anything further, I want to thank
 4
    the parties. I think I have already, and I'll look forward to
5
    the consent judgment. Thank you, we're in recess.
 6
    (Whereupon the proceedings concluded at 10:27 a.m.)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```

1	REPORTER'S CERTIFICATION
2	
3	I, TERI VERES, do hereby certify that I am duly
4	appointed and qualified to act as Official Court Reporter for
5	the United States District Court for the District of Arizona.
6	I FURTHER CERTIFY that the foregoing pages
7	constitute a full, true, and accurate transcript of all of
8	that portion of the proceedings contained herein, had in the
9	above-entitled cause on the date specified therein, and that
10	said transcript was prepared under my direction and control.
11	DATED at Phoenix, Arizona, this 19th of
12	May, 2023.
13	s/Teri Veres
14	TERI VERES, RMR, CRR
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	